专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

2. 发明授权

KR100352571B1 배합호르몬피임약제 失效
公开(公告)号：KR100352571B1
公开(公告)日：2003-01-06
申请号：KR1019960705421
申请日：1995-03-30
申请人： 바이엘 파마 악티엔게젤샤프트
发明人： 라흐니트,우르술라 , 뒤스터베르그,베른트 , 스포나,위르겐
IPC分类号： A61K31/57 , A61K31/565
CPC分类号： A61K31/565 , A61K31/567 , A61K31/57 , Y10S514/843 , A61K2300/00
摘要： PCT No. PCT/EP95/01190 Sec. 371 Date Dec. 16, 1996 Sec. 102(e) Date Dec. 16, 1996 PCT Filed Mar. 30, 1995 PCT Pub. No. WO95/26730 PCT Pub. Date Oct. 12, 1995A pharmaceutical combination preparation with two hormone components that are manufactured physically separately in a packaging unit and that are intended for time-sequential oral administration, which in each case consist of a number of daily dosage units that are placed physically separately and are individually removable in the packaging unit. As a hormonal active ingredient, a first hormone component contains in combination an estrogen preparation and, in at least a dosage that is sufficient to inhibit ovulation, a gestagen preparation, and as a hormonal active ingredient the second hormone component contains only an estrogen preparation. The first hormone component comprises 23 or 24 daily units and the second hormone component comprises 4 to 10 daily units. The total number of hormone daily units is equal to the total number of days of the desired cycle, but at least 28 days in length. This combination preparation is used for female birth control, and allows for an estrogen content that is as low as possible in each individual dosage unit and also has a low total hormone content per administration cycle, with high contraceptive reliability, low incidence of follicular development, and satisfactory cycle control, with reliable avoidance of intracyclic menstrual bleeding as well as of undesirable side-effects.\!
摘要翻译： PCT No.PCT / EP95 / 01190 Sec。 371日期1996年12月16日 102（e）日期1996年12月16日PCT申请日1995年3月30日PCT Pub。 WO95 / 26730 PCT Pub。日期1995年10月12日具有两种激素成分的药物组合制剂，其在生理学上分开制造在包装单元中并且用于时间顺序口服给药，其在每种情况下由多个日常剂量单位组成，所述日剂量单位被物理分开并可在包装单元中单独拆卸。作为激素活性成分，第一种激素成分包含雌激素制剂和至少足以抑制排卵的剂量的孕激素制剂，并且作为激素活性成分，第二种激素成分仅包含雌激素制剂。第一个激素成分包含23或24个日常单位，第二个激素成分包含4到10个日常单位。激素每日单位的总数等于所需周期的总天数，但至少为28天。该组合制剂用于女性避孕，并允许每个单位剂量单位中的雌激素含量尽可能低，并且每个给药周期的总激素含量低，具有高避孕可靠性，卵泡发育的低发生率，以及令人满意的周期控制，可靠地避免周期性月经出血以及不良副作用。

IPRDB

热门服务

关于我们

友情链接

联系方式